Tag: material

Acquisition expands Nagase America's coatings capabilities with dedicated testing, training, and technical innovation lab in Costa Mesa, CaliforniaITASCA, Ill., June 10, 2026 /PRNewswire/ -- Nagase...

Dalfen Industrial Accelerates Southeast Expansion with Fort Lauderdale Portfolio Acquisition

CALGARY, AB, June 10, 2026 /PRNewswire/ - High Tide Inc. ("High Tide" or the "Company") (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward...

BANGALORE, India, June 10, 2026 /PRNewswire/ -- ...

/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/TORONTO, June 10, 2026 /CNW/ - Power...

GREATER SUDBURY, ON, June 10, 2026 /CNW/ - Frontier Lithium Inc. ("Frontier") announces that it has entered into a non-binding memorandum of understanding (the...

Selected as the lead organization for a major government-backed initiative to accelerate commercialization of bio-based 3-HP through pilot-scale investments.Establishing an integrated R&D value chain...

New Brand Combines Proven Genetics, German Cultivation Expertise, and Rigorous Quality Standards to Support Patients and Healthcare Professionals Across Germany

New Brand Combines Proven Genetics, German Cultivation Expertise, and Rigorous Quality Standards to Support Patients and Healthcare Professionals Across Germany

Trading to begin at market open on Monday, June 15, 2026TORONTO, June 10, 2026 /CNW/ - Hemlo Mining Corp. (TSXV: HMMC) (OTCQX: HMMCF) (the...

TAIPEI and LONDON, June 10, 2026 /PRNewswire/ -- KINGSTEEL recently visited D3O, a global leader in advanced protection materials, where the two companies officially...

A new cellulose-based material platform developed in Finland responds to tightening regulatory requirements and industry pressure to both replace and reduce plastic in packaging,...

AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced the pricing of its previously announced a public offering of 10,879,376 shares of its common stock at a public offering price per share of $4.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,870,624 shares of its common stock at a public offering price of $3.9999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.0001 per share and are exercisable immediately. The aggregate gross proceeds to Shattuck from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and other offering expenses payable by Shattuck, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on June 11, 2026, subject to the satisfaction of customary closing conditions. In addition, Shattuck has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,812,500 shares of its common stock at the public offering price, less underwriting discounts and commissions.